Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but stra…
$276.22+1.43%
报价 2026-11-06
市值
$664.95B
EV
$595.56B
PE (TTM)
21.3x
预期 PE (FY2026)
24.9x
52 周区间距高点 -0.8%
$188.41$278.43
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.1x | 10.65 → 11.60（1.1x） | 23.8 |
| FY+32028-12 | 1.2x | 10.65 → 13.97（1.3x） | 19.8 |
毛利率 73% · TTM 收入 $99335M · 基数 EPS 10.65（调整后）
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| JNJJohnson & Johnson | $664.95B | +1.4% | +7.6% | 73% | 21.3x | 14.9x | 34.0x | |
| ABBVAbbVie Inc. | $514.78B | +1.1% | +10.4% | 73.3% | 86.3x | 15.1x | 27.7x | GARP |
| MRKMerck & Co., Inc. | $361.96B | -0.2% | +3.6% | 73.5% | 121.5x | 30.7x | 23.5x | |
| UNHUnitedHealth Group Incorporated | $353.79B | -0.4% | -0.9% | 18.5% | 20.3x | 13.0x | 22.1x | |
| NVSNovartis AG | $307B | +0.4% | – | 76% | 20.2x | 13.5x | – | |
| AZNAstraZeneca PLC | $289.13B | -0.2% | – | 78.2% | 27.5x | 15.4x | – | |
| AMGNAmgen Inc. | $248.92B | +0.0% | +4.0% | 70.5% | 24.4x | 12.5x | 30.7x | |
| GILDGilead Sciences, Inc. | $207B | -0.4% | +4.1% | 81.1% | 20.0x | 14.5x | 21.9x | |
| NVONovo Nordisk A/S | $177.74B | +0.0% | – | 78.2% | 10.3x | 7.2x | – | Cheap |
| 同行中位数 | – | – | +4.0% | 74.8% | 22.4x | 14.0x | 23.5x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-09-27 Q3 2026 | 2026-06-28 Q2 2026 | 2026-03-29 Q1 2026 | 2025-12-28 Q4 2025 | 2025-09-28 Q3 2025 | 2025-06-29 Q2 2025 | 2025-03-30 Q1 2025 | 2024-12-29 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $25.4B | $25.31B | $24.06B | $24.56B | $23.99B | $23.74B | $21.89B | $22.52B |
| Gross Margin | 73% | 68.2% | 66.3% | 67.6% | 69.6% | 67.9% | 66.4% | 68.3% |
| Operating Margin | 25.1% | 28.3% | 26.6% | 22.8% | 29.6% | 28.7% | 28.8% | 17.1% |
| Net Income | $210M | $5.53B | $5.24B | $5.12B | $5.15B | $5.54B | $11B | $3.43B |
| Diluted EPS | 0.09 | 2.27 | 2.14 | 2.1 | 2.12 | 2.29 | 4.54 | 1.41 |
| Operating Cash Flow | $7.72B | $8.62B | $2.51B | $7.31B | $9.17B | $3.88B | $4.17B | $6.98B |